Helix BioMedix, Inc.

DUBLIN--( BUSINESS WIRE )--The "Stretch Marks Treatment: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Stretch Marks Treatment estimated at US$1.4 Billion in the year 2020, is projected to reach a revised size of US$1.8 Billion by 2027, growing at a CAGR of 3.8% over the analysis period 2020-2027. Topical Products, one of the segments analyzed in the report, is projected to record a 4% CAGR and reach US$1.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Lasers segment is readjusted to a revised 3.5% CAGR for the next 7-year period. The U.S. Market is Estimated at $376.5 Million, While China is Forecast to Grow at 6.9% CAGR The Stretch Marks Treatment market in the U.S. is estimated at US$376.5 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$386.2 Million by the year 2027 trailing a CAGR of 6.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.2% and 2.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$256.3 Million by the year 2027. Microdermabrasion Segment to Record 3.1% CAGR In the global Microdermabrasion segment, USA, Canada, Japan, China and Europe will drive the 3.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$93.6 Million in the year 2020 will reach a projected size of US$112.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Latin America will expand at a 3.9% CAGR through the analysis period. Select Competitors (Total 46 Featured) - Basq Skincare Clarins Group Cynosure, Inc. Dermaclara, Inc. E.T. Browne Drug Co., Inc. Ellipse, a Candela Company Helix Biomedix, Inc. Laboratoires Expanscience Mama Mio US Inc. Merz North America, Inc. Syneron Medical Ltd. The Boppy Company, LLC. Union-Swiss (Pty) Ltd. Weleda AG What's New for 2022? Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to digital archives and Research Platform Complimentary updates for one year Key Topics Covered: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Stretch Marks Treatment - Global Key Competitors Percentage Market Share in 2022 (E) Impact of Covid-19 and a Looming Global Recession Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS 4. GLOBAL MARKET PERSPECTIVE III. MARKET ANALYSIS IV. COMPETITION For more information about this report visit https://www.researchandmarkets.com/r/mhzv0j

Recently added to the BioPortfolio report store, Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015 is a new report from Global Markets Direct published on 2015-07-30. This 68-page report is available in PDF from $2000. Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015 Summary Global Markets Direct’s, ‘Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015’, provides an overview of the Onychomycosis (Tinea Unguium)’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Onychomycosis (Tinea Unguium), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Onychomycosis (Tinea Unguium) and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Onychomycosis (Tinea Unguium) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Onychomycosis (Tinea Unguium) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Onychomycosis (Tinea Unguium) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage … Table of Contents Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Onychomycosis (Tinea Unguium) Overview 8 Therapeutics Development 9 Pipeline Products for Onychomycosis (Tinea Unguium) - Overview 9 Pipeline Products for Onychomycosis (Tinea Unguium) - Comparative Analysis 10 Onychomycosis (Tinea Unguium) - Therapeutics under Development by Companies 11 Onychomycosis (Tinea Unguium) - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Onychomycosis (Tinea Unguium) - Products under Development by Companies 15 Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development 16 Anacor Pharmaceuticals, Inc. 16 Eisai Co., Ltd. 17 Helix BioMedix, Inc. 18 Hexima Limited 19 Meiji Seika Pharma Co., Ltd. 20 Moberg Pharma AB 21 NAL Pharmaceuticals Ltd. 22 Nihon Nohyaku Co., Ltd. 23 Novabiotics Limited 24 Nuvo Research Inc. 25 Viamet Pharmaceuticals, Inc. 26 Onychomycosis (Tinea Unguium) - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 AN-2718 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 E-1224 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 ELS-160 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 HB-1275 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 HXP-124 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 luliconazole - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 ME-1111 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 NAL-3216 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 NP-213 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 terbinafine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 terbinafine - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 VT-1161 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Onychomycosis (Tinea Unguium) - Recent Pipeline Updates 53 Onychomycosis (Tinea Unguium) - Dormant Projects 58 Onychomycosis (Tinea Unguium) - Discontinued Products 61 Onychomycosis (Tinea Unguium) - Product Development Milestones 62 Featured News & Press Releases 62 Mar 26, 2015: Moberg Pharma Announces Grant of EU Patent for MOB-015 Related to Topical… For more information open Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2015. SKU: GMDHC6868IDB

BOTHELL, Wash., Dec. 4 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc. , a developer of bioactive peptides, today announced that Timothy J. Falla, Ph. D, Chief Scientific Officer, will be presenting results of a new study demonstrating antifungal efficacy of its novel family of lipo-peptides in a preclinical infection model at IBC's 7th Annual EuroTIDES 2006 conference on Oligonucleotide, RNAi and Peptide Technology. The conference will be held at the Radisson SAS in Hamburg, Germany, on December 4th through the 7th. Dr. Falla's presentation "Synthetic Lipohexapeptides: A Novel Class of Anti-infective" will take place on December 5th at 12:20 pm. Helix BioMedix's lipo-peptide compounds exhibited significant efficacy both clinically and mycologically in a recent animal study, and leading investigators have concluded that further evaluation is warranted. The independent research study was conducted by Mahmoud A. Ghannoum, Ph.D. at the Center for Medical Mycology, University Hospitals of Cleveland/Case Western Reserve University. "This study was a component of our proof of concept evaluation for these molecules to be used for dermatological application and we are very pleased with the results," commented Dr. Falla. "Due to the broad spectrum of activity of this new class of potential anti-infective, the results of previous bacterial infection models, and the results of this latest study, we have confidence that there is great potential for addressing a wide range of pathogen-based dermatological indications in a market that is estimated at $665 million." The study involved use of a guinea pig model, which was developed and used earlier at the Center for Medical Mycology in the pre-clinical evaluation of terbinafine and itraconazole, the two FDA-approved antifungal agents currently on the market for treatment of onychomycosis, or fungal nail infections. The experimental animals were infected with conidia, which was applied on abraded skin, and then were divided into groups, including three treatment groups of peptides, an untreated control, vehicle control and a positive control (terbinafine). Three days after inoculation, animals were treated topically once daily for a period of seven days. At the end of treatment, hair samples were removed for mycologic evaluation of fungal growth at the hair root and clinical assessment was made of the infected skin area. Test compounds HB 1275 and HB 1148 showed significant efficacy both clinically and mycologically. About Helix BioMedix Helix BioMedix, Inc. is a biopharmaceutical company that has a portfolio of issued patents that covers six distinct classes of peptides, covering over 100,000 unique peptide sequences. The company's mission is to become the industry leader in developing and commercializing small proteins known as bioactive peptides. The antimicrobial and wound healing properties of these peptides qualify them for inclusion in a wide range of both pharmaceutical and consumer products. The company is currently focused on the development of selected peptides as topical anti-infectives and in wound healing. Non- pharmaceutical applications being pursued by Helix BioMedix include adjuvants for cosmetics/cosmeceuticals, personal care, plant health, animal health and wide-spectrum biocides. More information about the company and its proprietary peptides can be found on the company's website at . Contact: Investor Relations: Cameron Associates Alison Ziegler, 212-554-5469 alison@cameronassoc.com Helix BioMedix, Inc. CONTACT: Investor Relations: Alison Ziegler of Cameron Associates,+1-212-554-5469 or alison@cameronassoc.com, for Helix BioMedix, Inc. Web site: